Overview
Daiichi Sankyo Co., Ltd. is a global pharmaceutical company that discovers, develops, and delivers medicines. Its portfolio spans oncology, cardiovascular medicines, other pharmaceuticals, and vaccines, with antibody-drug conjugates among its defining oncology technologies.[1][2] Its businesses and products serve markets across Japan, the Americas, Europe, and Asia and Oceania.[3][4]
The company’s stated purpose is to contribute to the enrichment of quality of life around the world; its mission is to create innovative pharmaceuticals for diverse medical needs.[5] As of March 31, 2026, Daiichi Sankyo reported 20,171 Group employees and operations in 32 countries and regions.[6] For the fiscal year ended March 31, 2026, revenue was ¥2,123.0 billion.[7] [3][1][2][4][5][6][7]
Products & services
Daiichi Sankyo’s products include prescription medicines across oncology, cardiovascular disease, pain and other therapeutic areas, as well as vaccines. Named products include ENHERTU (trastuzumab deruxtecan), a HER2-directed antibody-drug conjugate (ADC); DATROWAY (datopotamab deruxtecan), a TROP2-directed ADC; LIXIANA (edoxaban), an anticoagulant; and TARLIGE (mirogabalin), a treatment for neuropathic pain. Approved uses and product availability vary by market.[2][8]
Its DXd ADC platform combines a monoclonal antibody with a topoisomerase-I inhibitor payload derived from exatecan, using a cleavable linker. ENHERTU targets HER2, while DATROWAY targets TROP2.[9] Daiichi Sankyo also has product-related collaboration and supply responsibilities: ENHERTU is jointly developed and commercialized with AstraZeneca, with Daiichi Sankyo retaining rights in Japan; Daiichi Sankyo is responsible for manufacturing and supply of DATROWAY under its global collaboration.[10][11]
ENHERTU generated ¥819.5 billion in FY2025, approximately 38.6% of consolidated revenue of ¥2,123.0 billion. In FY2026 Q1, ENHERTU revenue was ¥239.8 billion and DATROWAY revenue was ¥23.9 billion; both figures included milestone payments.[7][12] [13][2][8][9][10][11][7][12]
Geographic presence
For the fiscal year ended March 31, 2026, Daiichi Sankyo reported revenue of ¥2,123.0 billion. By region, Japan accounted for ¥580.1 billion (27.3%), North America ¥749.4 billion (35.3%), Europe ¥497.4 billion (23.4%), and Other regions ¥296.2 billion (14.0%). “Other regions” is the company’s reported category.[14]
The company reports 45 group companies across 32 countries and regions, with 13 research facilities in 3 countries or regions and 13 production locations in 6. Its overseas research institutes include locations in Boston, Munich, and San Diego.[6][15] [14][6][15]
Business segments
Daiichi Sankyo reports one operating segment: **pharmaceuticals**, encompassing its pharmaceutical business. It does not disclose separate operating-segment revenue contributions; on that basis, pharmaceuticals represents 100% of reported segment activity. The latest full-year figures are for FY2025, ended March 31, 2026.[16]
As a separate view—not an operating-segment breakdown—FY2025 sales by customer location were approximately 27.3% Japan, 35.3% North America, 23.4% Europe, and 14.0% other regions.[14] [16][14]
Company history
Daiichi Sankyo traces its roots to two Japanese pharmaceutical companies. Sankyo Shoten was established in 1899, the year it launched Taka-Diastase; it later introduced Adrenalin in 1902. Daiichi’s predecessor, Arsemin Shokai, was founded in 1915 and became Daiichi Pharmaceutical Co., Ltd. in 1918. Sankyo began overseas expansion with a New York branch in 1918 and a Taipei branch in 1920.[17][18][19]
The companies developed and marketed medicines internationally in the decades before their merger. Notable milestones included Daiichi’s launch of Cravit® (levofloxacin) in 1993 and Sankyo’s development of Mevalotin® and olmesartan. Sankyo and Daiichi Pharmaceutical established DAIICHI SANKYO COMPANY, LIMITED by stock transfer on September 28, 2005; the merged operating company began business on April 1, 2007.[18][17][20][21]
After the merger, Daiichi Sankyo expanded its biotechnology and oncology capabilities through acquisitions, including U3 Pharma in 2008 and Plexxikon in 2011. It also acquired a majority stake in Ranbaxy in 2008, but exited the investment after Sun Pharma’s merger with Ranbaxy was completed in 2015. In 2019, Daiichi Sankyo and AstraZeneca entered a global development and commercialization collaboration for trastuzumab deruxtecan, later marketed as ENHERTU; the medicine received accelerated approval in the United States that year.[22][23][24][25][10][26] [17][18][19][20][21][22][23][24][25][10][26]
Sources
- www.daiichisankyo.com[1]
- www.daiichisankyo.com[2]
- DAIICHI SANKYO CO LTD — Presentation (2025 Q 3)[3][13]
- www.daiichisankyo.com[4]
- www.daiichisankyo.com[5]
- www.daiichisankyo.com[6]
- www.daiichisankyo.com[7]
- www.daiichisankyo.com[8]
- www.daiichisankyo.com[9]
- www.daiichisankyo.com[10]
- www.daiichisankyo.com[11]
- www.daiichisankyo.com[12]
- www.daiichisankyo.com[14]
- www.daiichisankyo.com[15]
- www.daiichisankyo.com[16]
- www.daiichisankyo.com[17]
- www.daiichisankyo.com[18]
- www.daiichisankyo.com[19]
- www.daiichisankyo.com[20]
- www.daiichisankyo.com[21]
- www.daiichisankyo.com[22]
- www.daiichisankyo.com[23]
- www.daiichisankyo.com[24]
- www.daiichisankyo.com[25]
- www.daiichisankyo.com[26]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore DAIICHI SANKYO CO LTD in Finbar ↗